Singapore markets closed

Straits Times Index
3,348.87
+12.28(+0.37%)
S&P 500
5,286.81
+9.30(+0.18%)
Dow
38,599.77
-86.55(-0.22%)
Nasdaq
16,839.04
+104.02(+0.62%)
Bitcoin USD
69,809.41
+1,698.02(+2.49%)
CMC Crypto 200
1,505.70
+37.77(+2.57%)

BMY Jun 2024 38.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.2000

0.0000

(0.00%)

As of 02:45PM EDT. Market open.

Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
Business Wire
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Zacks
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.